Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist

Area of Science:

• Molecular Biology
• Cellular Biology
• Pharmacology

Background:

• Necroptosis, a programmed cell death pathway, significantly contributes to inflammatory diseases.
• Targeting necroptosis offers therapeutic promise, but effective inhibitors are limited.
• Receptor-interacting protein kinases 1 (RIPK1) is a key regulator of necroptosis.

Purpose of the Study:

• To identify novel inhibitors of necroptosis.
• To evaluate Vemurafenib, an FDA-approved anti-cancer drug, as a necroptosis inhibitor.
• To elucidate the mechanism of Vemurafenib's action on RIPK1 and necroptosis.

Main Methods:

• Drug screening and identification of Vemurafenib as a necroptosis inhibitor.
• Biochemical assays to assess RIPK1 kinase activity inhibition.
• Cellular assays to evaluate necrosome complex formation and necroptosis.
• In vivo studies using animal models of necroptosis-associated diseases.

Main Results:

• Vemurafenib directly binds to RIPK1, inhibiting its kinase activity and downstream signaling.
• Vemurafenib prevents necrosome complex assembly, thereby blocking necroptosis.
• Vemurafenib stabilizes RIPK1 in an inactive conformation via a unique allosteric binding site.
• Pretreatment with Vemurafenib demonstrated significant protection in vivo against necroptosis-related conditions.

Conclusions:

• Vemurafenib acts as a potent RIPK1 antagonist, effectively inhibiting necroptosis.
• The findings provide strong preclinical evidence for repurposing Vemurafenib in necroptosis-related inflammatory diseases.
• Vemurafenib represents a promising therapeutic candidate for conditions involving dysregulated necroptosis.